Regeneron Pharmaceuticals, Inc. $REGN Position Trimmed by Tema Etfs LLC

Tema Etfs LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,300 shares of the biopharmaceutical company’s stock after selling 1,549 shares during the period. Tema Etfs LLC’s holdings in Regeneron Pharmaceuticals were worth $2,727,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the period. American Assets Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $427,000. Integrated Wealth Concepts LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 55.5% during the fourth quarter. Integrated Wealth Concepts LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $828,000 after acquiring an additional 415 shares during the period. Lido Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 9.5% during the fourth quarter. Lido Advisors LLC now owns 2,314 shares of the biopharmaceutical company’s stock valued at $1,649,000 after acquiring an additional 201 shares during the period. Finally, Schonfeld Strategic Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 475.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 22,388 shares of the biopharmaceutical company’s stock valued at $15,948,000 after acquiring an additional 18,496 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $586.96 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,210.97. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $62.21 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 1.96 and a beta of 0.33. The firm has a 50-day moving average of $554.52 and a two-hundred day moving average of $589.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the prior year, the company earned $11.56 EPS. Regeneron Pharmaceuticals’s revenue was up 3.6% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a report on Monday, June 9th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Argus downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.